Clinical Trial

A Study to Evaluate ALN-6222 in Participants With Obesity

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a first in human, randomized, double-blind (DB), placebo-controlled, single ascending dose (SAD), Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of ALN-6222 administered subcutaneously (SC) in adult participants with obesity.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-30
Trial Details
NCT Number NCT07624071
Lead Sponsor Alnylam Pharmaceuticals
Conditions Obesity
Enrollment 88 participants
Start Date 2026-06-04
Primary Completion 2027-12-14 (estimated)
Study Completion 2027-12-14 (estimated)
Updated on ClinicalTrials.gov 2026-08-12